Macular pigments in retinal degenerative processes

Close metadata

Macular pigments (MP) — carotenoids, which determine the structure of the central part of the retina, play an important role in the work of its foveolar part. The main function of MP is to maintain full functionality of the macular area of the retina, which is based on the possibility of reducing color aberrations in the absorption of blue light and patients’ ability for dark adaptation. Epidemiological studies have revealed a direct correlation between the low MP and the increased risk of developing age-related macular degeneration. However, global studies on the issue such as CARMA, CARMA, AREDS I, AREDS II, Rotterdam Study, and TOZAL study have proved the possibility of correcting the level of MP in the retina when they’re taken as food additives, effectively reducing the risk of developing degenerative processes in the retina. In addition, studies have determined the optimal formula for food additives to stabilize the functionality of the macular area. The most important components of the additive have been shown include lutein, zeaxanthin, ascorbic acid, selenium, zinc, α-tocopherol acetate.

Keywords:

macular degeneration

macular pigments

lutein

Authors:

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

SPIN RSCI: 3552-7061
Scopus AuthorID: 6508005851
ResearcherID: C-3026-2014
ORCID: 0000-0002-5507-8775

List of references:

Bikbov MM, Fayzrakhmanov RR. Vliyaniye antivazoproliferativnoy terapii na morfofunktsional’nyye osobennosti klassicheskoy khorioidal’noy neovaskulyarizatsii u patsiyentov s vozrastnoy makulyarnoy degeneratsiyey. Vestnik Rossiyskoy voyenno-meditsinskoy akademii. 2016;2(54):111-115. (In Russ.)
Bone RA, Landrum JT, Friedes LM, Gomez CM, Kilburn MD, Menendez E, Vidal I, Wang W. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997;64(2):211-218.
Trieschmann M, van Kuijk FJ, Alexander R, Hermans P, Luthert P, Bird AC, Pauleikhoff D. Macular pigment in the human retina: histological evaluation of localization and distribution. Eye (Lond). 2008;22(1):132-137.
Snodderly DM, Brown PK, Delori FC, Auran JD. The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):660-673.
Bikbov MM, Fayzrakhmanov RR, Gil’manshin TR. Selective symptomatic therapy of macular edema due to occlusive processes in retinal venous system. Vestnik oftal’mologii. 2017;133(2):18-21. (In Russ.)
https://doi.org/10.17116/oftalma2017133218-21
Loughman J, Davison PA, Nolan JM, et al. Macular pigment and its contribution to visual performance and experience. J Optom. 2010;3:74-90.
SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Age-Related Eye Disease Study Research Group. Arch Ophthalmol. 2007;125(9):1225-1232.
Age-Related Eye Disease Study 2 Research Group. JAMA. 2013;309(19):2005-2015.
Akuffo KO, Nolan JM, Howard AN, Moran R, Stack J, Klein R, Klein BE, Meuer SM, Sabour-Pickett S, Thurnham DI, Beatty S. Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration. Eye (Lond). 2015;29(7):902-912.
Stahl W. Macular carotenoids: lutein and zeaxanthin. Dev Ophthalmol. 2005;38:70-88.
Nolan JM, Meagher K, Kashani S, Beatty S. What is meso-zeaxanthin, and where does it come from? Eye (Lond). 2013;27(8):899-905.
Bone RA, Landrum JT, Cains A. Optical density spectra of the macular pigment in vivo and in vitro. Vision Res. 1992;32(1):105-110.
Stringham JM, Fuld K, Wenzel AJ. Spatial properties of photophobia. Invest Ophthalmol Vis Sci. 2004;45(10):3838-3848.
Wenzel AJ, Fuld K, Stringham JM, Curran-Celentano J. Macular pigment optical density and photophobia light threshold. Vision Res. 2006;46(28):4615-4622.
Stringham JM, Hammond BR. The glare hypothesis of macular pigment function. Jr Optom Vis Sci. 2007;84(9):859-864.
Nolan JM, Loughman J, Akkali MC, Stack J, Scanlon G, Davison P, Beatty S. The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vision Res. 2011;51(5):459-469.
Bikbov MM, Fayzrakhmanov RR, Yarmukhametova AL. Central retinal changes after ranibizumab injection for wet age-related macular degeneration. Vestnik oftal’mologii. 2015;131(4):60-65. (In Russ.) https://doi.org/10.17116/oftalma2015131160-65
Edge R, McGarvey DJ, Truscott TG. The carotenoids as anti-oxidants--a review. J Photochem Photobiol B. 1997;41(3):189-200.
Ma L, Dou HL, Wu YQ, Huang YM, Huang YB, Xu XR, Zou ZY, Lin XM. Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis. Br J Nutr. 2012;107(3):350-359.
Neelam K, Hogg RE, Stevenson MR, Johnston E, Anderson R, Beatty S, Chakravarthy U. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiol. 2008;15(6):389-401.
Trieschmann M, Beatty S, Nolan JM, Hense HW, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental luteinand zeaxanthin: The LUNA study. Experimental Eye Research. 2007;84:718-728.
Age-Related Eye Disease Study Group. A randomized, placebo controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and visual loss. Arch Ophthalmol. 2001;119:1417-1436.
Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, Hofman A, de Jong PT, Vingerling JR, Klaver CC. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study. Arch Ophthalmol. 2011;129(6):758-766.
Cangemi FE. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol. 2007;26(7):3.

Close metadata